A Multicentre, Parallel Group Open-label Randomised Controlled Non-Inferiority Phase 3 Trial, of ceftolozane-tazobactam versus meropenem for definitive treatment [...] MERINO-3 (2019–2022)
- Grant type:
- Merck Sharp & Dohme Australia
- Researchers:
-
-
- Funded by:
- Merck, Sharp & Dohme
